21 CFR 803.50
If I am a manufacturer, what reporting requirements apply to me?
- Inspections citing it: 990
- Of those classified, ended OAI: 27%
- Last cited: FY2026
Inspections Citing It by Fiscal Year
Sites in and outside the US, FY2017 to Oct 20, 2026.
Paragraphs Cited
As FDA posts them, all years.
- 803.50(a)(2)
- 549 · Individual Report of Malfunction
- 803.50(a)(1)
- 402 · Report of Death or Serious Injury
- 803.50(b)(1)
- 29 · Reporting Information Reasonably Known
- 803.50(b)(3)
- 10 · Conducting an Investigation
Regulation Text
eCFR, as of Nov 6, 2026(a) If you are a manufacturer, you must report to us the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that you receive or otherwise become aware of information, from any source, that reasonably suggests that a device that you market:
(1) May have caused or contributed to a death or serious injury or
(2) Has malfunctioned and this device or a similar device that you market would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur.
(b) What information does FDA consider “reasonably known” to me?
(1) You must submit all information required in this subpart E that is reasonably known to you. We consider the following information to be reasonably known to you:
(i) Any information that you can obtain by contacting a user facility, importer, or other initial reporter;
(ii) Any information in your possession; or
(iii) Any information that you can obtain by analysis, testing, or other evaluation of the device.
(2) You are responsible for obtaining and submitting to us information that is incomplete or missing from reports submitted by user facilities, importers, and other initial reporters.
(3) You are also responsible for conducting an investigation of each event and evaluating the cause of the event. If you cannot submit complete information on a report, you must provide a statement explaining why this information was incomplete and the steps you took to obtain the information. If you later obtain any required information that was not available at the time you filed your initial report, you must submit this information in a supplemental report under § 803.56 in accordance with the requirements of § 803.12(a).
Recently Cited Sites
Newest inspections citing this section; each opens the site- King Brand Healthcare ProductsUnited States · Jul 24, 2026
- BIOPSYBELL S.R.L.Italy · Jul 23, 2026
- Biowave CorporationUnited States · May 26, 2026
- Biofilm, Inc.United States · May 19, 2026
- Mobia Medical IncUnited States · Mar 19, 2026
- Fudakang Industrial Co LtdChina · Mar 12, 2026
- BioTissue Holdings IncUnited States · Feb 18, 2026
- MedLine Industries, LP (NAMIC Division)United States · Dec 12, 2025
- Mid Central Medical, LLC.United States · Dec 9, 2025
- Sol-Millennium Medical Inc.United States · May 8, 2025
- Contract Medical International spol. sr.o.Czechia · Nov 9, 2022
- Nihon Kohden America LLCUnited States · Apr 30, 2019
Counts are inspections with posted citations that cite any paragraph of the section, once per inspection, from FDA's Data Dashboard. OAI share is over inspections FDA finally classified. Text from eCFR, the official online CFR. FDA Data Dashboard and eCFR